Skip to main content

Simpson Thacher & Bartlett and Anderson Mori & Tomotsune have represented Blackstone in its 242 billion yen ($2.3 billion) acquisition of Takeda Consumer Healthcare, which turned to Nishimura & Asahi for advice. The deal is expected to close in March 2021.

Takeda Consumer Healthcare is a subsidiary of Takeda Pharmaceutical and a leading provider of over the counter (OTC) medicines in Japan.

According to Reuters, Takeda Pharmaceutical has been selling its OTC assets worldwide as it seeks to refocus its business and reduce debt from last year’s $59 billion acquisition of Shire.

The deal marks Blackstone’s second private equity transaction in Japan’s healthcare sector, following the acquisition of AYUMI Pharmaceutical in 2019.

Simpson Thacher partners Tony King, Shahpur Kabraji and Jonathan Goldstein led on the transaction. Meanwhile, the Nishimura team was led by partners Yo Ota, Hiroko Shibata and Taeko Morita.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

CAM, Trilegal, Sidley act on Godrej’s $700 mln QIP

by Nimitt Dixit |

Cyril Amarchand Mangaldas has continued its strong run in qualified institutional market deals, advising Godrej Properties on its $708 million equity offering via a QIP. Trilegal and Sidley Austin advised the bookrunning lead managers.

Deals

SAM, CAM, Latham guide India’s largest QIP in 2024

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Indian food delivery giant Zomato on its $1 billion equity offering through a qualified institutional placement of shares, with Shardul Amarchand Mangaldas & Co and Latham & Watkins advising the bookrunning lead manager Morgan Stanley India.

Deals

Hogan Lovells, Khaitan guide $890 mln Varun Bev QIP

by Nimitt Dixit |

Khaitan & Co and Hogan Lovells served as Indian and international counsel on the $890 million qualified institutional placement of shares by Varun Beverages, the leading bottler of beverage major PepsiCo.